Sinoviortesis radioisotópica en pacientes en edad pediátrica y adolescentes con hemofilia / Radioisotope synoviorthesis in paediatric and adolescent patients with haemophilia

Objetivo. Valorar la eficacia terapéutica y las complicaciones de la sinoviortesis radioisotópica observadas en pacientes en edad pediátrica y adolescentes con hemofilia. Material y métodos. Estudio prospectivo de cohorte histórica en el que se incluyó, de forma consecutiva, a 20 pacientes varones con hemofilia (edad media 13,1 años, rango: 4-17 años). El diagnóstico de sinovitis se estableció clínicamente y se confirmó por radiología simple o RMN). Evaluación mediante la clasificación de Fernández-Palazzi. Criterios de inclusión: menores de 18 años de edad con hemofilia y más de un hemartros en menos de 3 meses, manteniéndose una sinovitis crónica a pesar de intensificar el tratamiento profiláctico. Criterios de exclusión: cualquier contraindicación para la realización de la sinoviortesis. Se realizaron 27 sinoviortesis radioisotópicas con citrato de 90Y colidal o sulfuro 186Re coloidal. La eficacia del procedimiento se evaluó a los 6 meses mediante comparación clínica pre- y postratamiento. Tiempo medio de seguimiento: 64,9 meses (rango 18-109 meses). Resultados. En 19 de las 27 sinoviortesis (70,3%) hubo una respuesta buena o excelente y en 8 articulaciones (29,7%), respuesta parcial. Se repitió el procedimiento en 3 articulaciones de 3 pacientes diferentes debido a la aparición de nuevo hemartros, obteniendo en todos los casos una respuesta buena o excelente. Apareció reacción inflamatoria postratamiento en 4 casos (14,8%), que mejoraron con tratamiento médico. No se observaron lesiones malignas ni premalignas durante el seguimiento. Conclusión. La sinoviortesis radioisotópica es un procedimiento efectivo, en pacientes en edad pediátrica y adolescentes con hemofilia, mínimamente invasivo, fácil de realizar, seguro y con complicaciones mínimas (AU)

Objective. To assess the outcome and adverse-effects of the radioisotope synoviorthesis in paediatric and adolescent patients with haemophilia. Material and Methods. Prospective study of historical cohort was conducted. A total of 20 consecutive haemophiliacs with a mean age of 13.1 years (range 4-17) were included with a mean follow-up of 64.9 months (range 18-109). The diagnosis of synovitis was established on the basis of clinical follow-up including radiological images (radiography and/or MRI). For evaluation, the classification proposed by Fernandez-Palazzi was used. Inclusion criteria: Patients aged less than 18 years old with haemophilia and more than one haemarthrosis in less than 3 months remaining a chronic synovitis despite prophylactic therapy intensification. Exclusion criteria: Any contraindication for radionuclide synoviorthesis. Twenty-seven radioisotope synoviorthesis with 90Y-citrate-colloid and/or 186Re-sulphide-colloid were done. The effectiveness of the procedure was assessed through pre and posttreatment clinical comparison at 6 months after radioisotope synoviorthesis. Results. Nineteen of the 27 synoviorthesis (70.3%) had a good or excellent response and 8 joints (29.7%) had partial response. It was necessary to repeat the procedure in 3 joints in 3 different patients, obtaining in all cases a good or excellent response. We appreciated inflammatory reaction after procedure in 4 cases (14.8%), which improved with analgesics and nonsteroidal anti-inflamatory drugs. None of the patients presented malignant or premalignant lesions during the follow-up. Conclusion. The radionuclide synoviorthesis is a very effective procedure in paediatric and adolescent patients with hemophilia, being a minimally invasive procedure, easy to perform, safe and with minimal side effects (AU)

Radioisotope synoviorthesis in paediatric and adolescent patients with haemophilia.

OBJECTIVE: To assess the outcome and adverse-effects of the radioisotope synoviorthesis in paediatric and adolescent patients with haemophilia. MATERIAL AND METHODS: Prospective study of historical cohort was conducted. A total of 20 consecutive haemophiliacs with a mean age of 13.1 years (range 4-17) were included with a mean follow-up of 64.9 months (range 18-109). The diagnosis of synovitis was established on the basis of clinical follow-up including radiological images (radiography and/or MRI). For evaluation, the classification proposed by Fernandez-Palazzi was used. INCLUSION CRITERIA: Patients aged less than 18 years old with haemophilia and more than one haemarthrosis in less than 3 months remaining a chronic synovitis despite prophylactic therapy intensification. EXCLUSION CRITERIA: Any contraindication for radionuclide synoviorthesis. Twenty-seven radioisotope synoviorthesis with (90)Y-citrate-colloid and/or (186)Re-sulphide-colloid were done. The effectiveness of the procedure was assessed through pre and posttreatment clinical comparison at 6 months after radioisotope synoviorthesis. RESULTS: Nineteen of the 27 synoviorthesis (70.3%) had a good or excellent response and 8 joints (29.7%) had partial response. It was necessary to repeat the procedure in 3 joints in 3 different patients, obtaining in all cases a good or excellent response. We appreciated inflammatory reaction after procedure in 4 cases (14.8%), which improved with analgesics and nonsteroidal anti-inflamatory drugs. None of the patients presented malignant or premalignant lesions during the follow-up. CONCLUSION: The radionuclide synoviorthesis is a very effective procedure in paediatric and adolescent patients with hemophilia, being a minimally invasive procedure, easy to perform, safe and with minimal side effects.

Neuroartropatía de Charcot / Charcot’s neuroarthropathy

La diabetes constituye en la actualidad la causa más frecuente de artropatía neuropática. El tarso suele ser la localización más frecuente de esta entidad. Desde el punto de vista clínico, su inicio insidioso con dolor y discretos signos inflamatorios del tarso suele conducir a una interpretación errónea por parte de los médicos que habitualmente atienden a estos pacientes (endocrinólogos, reumatológos, podólogos, etc.), lo que retrasa el diagnóstico con las consecuencias que esto puede comportar. En este trabajo se describen 4 casos de artropatía neuropática en pacientes diabéticos diagnosticados en nuestro servicio, y se hace especial mención a la sintomatología que debe orientar al diagnóstico de esta entidad en sus fases iniciales(AU)

Diabetes is the most common cause of neuropathic arthropathy. The most frequent localization is the tarsus. In clinical practice, the insidious painful onset and discrete inflammatory signs of this disease often lead to a mistaken interpretation by the physicians who usually manage these patients (endocrinologists, rheumatologists, podiatrists, etc.), delaying diagnosis with devastating consequences. We report four cases of neuropathic arthropathy in diabetic patients diagnosed in our service. The clinical features that may suggest a diagnosis in the early stages of this entity are stressed(AU)

[Charcot's neuroarthropathy]. / Neuroartropatía de Charcot.

Diabetes is the most common cause of neuropathic arthropathy. The most frequent localization is the tarsus. In clinical practice, the insidious painful onset and discrete inflammatory signs of this disease often lead to a mistaken interpretation by the physicians who usually manage these patients (endocrinologists, rheumatologists, podiatrists, etc.), delaying diagnosis with devastating consequences. We report four cases of neuropathic arthropathy in diabetic patients diagnosed in our service. The clinical features that may suggest a diagnosis in the early stages of this entity are stressed.

[Rheumatologic manifestations of chronic graft vs host disease. 4 case reports]. / Manifestaciones reumatológicas de la enfermedad injerto contra huésped crónica. A propósito de cuatro casos.

A description is given of four patients with the diagnosis of chronic graft-versus-host disease (cGVHD) who developed articular manifestations during the clinical course. One of the patients developed advanced lesions of scleroderma. The rheumatologic changes of the disease as well as other affections of organs, complications and prophylaxis are reviewed.

Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial.

Fibromyalgia is a painful syndrome of non-articular origin, predominantly involving muscles, and the commonest cause of chronic widespread musculoskeletal pain. The diversity of therapeutic programs for patients with fibromyalgia reflects both the lack of a known pathophysiology for this disorder and the low efficacy of the current therapies. We studied the efficacy of tenoxicam and bromazepan in the treatment of patients with fibromyalgia. One hundred and sixty-four patients from our Rheumatology Outpatient Clinic fulfilling the American College of Rheumatology criteria for the classification of fibromyalgia, with widespread pain at study entry. Each of the 164 patients was randomly assigned to 1 of 4 treatment groups: double placebo (P), tenoxicam (20 mg) + placebo (T), bromazepan (3 mg) + placebo (B)m or tenoxicam (20 mg) + bromazepan 3 mg (TB). Patient global assessment of disease, pain, sleep quality, morning stiffness, and number of tender points were evaluated at baseline and 8 weeks afterwards. At the end of the trial, 17%, 10%, 12%, and 29% of the P, T, B, and TB patients, respectively, had clinical improvement. A statistically significant difference was found only between the T and TB groups. Our data indicate that treatment with tenoxicam + bromazepan can be effective for some patients with fibromyalgia, but the differences with the placebo group were neither clinically nor statistically significant.